Navigation Links
Protein reveals diabetes risk many years in advance
Date:11/7/2012

When a patient is diagnosed with type 2 diabetes, the disease has usually already progressed over several years and damage to areas such as blood vessels and eyes has already taken place. To find a test that indicates who is at risk at an early stage would be valuable, as it would enable preventive treatment to be put in place.

Researchers at Lund University have now identified a promising candidate for a test of this kind. The findings have been published in the journal Cell Metabolism.

"We have shown that individuals who have above-average levels of a protein called SFRP4 in the blood are five times more likely to develop diabetes in the next few years than those with below-average levels", says Anders Rosengren, a researcher at the Lund University Diabetes Centre (LUDC), who has led the work on the risk marker.

Higher levels in diabetes patients

It is the first time a link has been established between the protein SFRP4, which plays a role in inflammatory processes in the body, and the risk of type 2 diabetes. Studies at LUDC, in which donated insulin-producing beta cells from diabetic individuals and non-diabetic individuals have been compared, show that cells from diabetics have significantly higher levels of the protein.

Link between inflammation and diabetes explained

It is also the first time the link between inflammation in beta cells and diabetes has been proven.

"The theory has been that low-grade chronic inflammation weakens the beta cells so that they are no longer able to secrete sufficient insulin. There are no doubt multiple reasons for the weakness, but the SFRP4 protein is one of them", says Taman Mahdi, main author of the study and one of the researchers in Anders Rosengren's group.

Fivefold risk increase

The level of the protein SFRP4 in the blood of non-diabetics was measured three times at intervals of three years. Thirty-seven per cent of those who had higher than average levels developed diabetes during the period of the study. Among those with a lower than average level, only nine per cent developed the condition.

"This makes it a strong risk marker that is present several years before diagnosis. We have also identified the mechanism for how SFRP4 impairs the secretion of insulin. The marker therefore reflects not only an increased risk, but also an ongoing disease process", says Anders Rosengren.

The marker works independently of other known risk factors for type 2 diabetes, for example obesity and age.

Motivation for lifestyle changes

"If we can point to an increased risk of diabetes in a middle-aged individual of normal weight using a simple blood test, up to ten years before the disease develops, this could provide strong motivation to them to improve their lifestyle to reduce the risk", says Anders Rosengren, adding:

"In the long term, our findings could also lead to new methods of treating type 2 diabetes by developing ways of blocking the protein SFRP4 in the insulin-producing beta cells and reducing inflammation, thereby protecting the cells."


'/>"/>
Contact: Anders Rosengren
Anders.Rosengren@med.lu.se
46-705-316-704
Lund University
Source:Eurekalert

Related medicine news :

1. Warwick scientists uncover how checkpoint proteins bind chromosomes
2. Specific protein triggers changes in neurons in brain reward center linked to cocaine addiction
3. Unusual protein helps regulate key cell communication pathway
4. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
5. RANK protein promotes the initiation, progression and metastasis of human breast cancer
6. Protein may represent a switch to turn off B cell lymphoma
7. Protein RAL associated with aggressive characteristics in prostate, bladder and skin cancers
8. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
9. Pivotal role for proteins -- from helping turn carbs into energy to causing devastating disease
10. New molecular structure offers first picture of a protein family vital to human health
11. Wayne State University researcher examines proteins role in diabetic retinopathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... , ... "I had a terrible time trying to get my grandson to ... the nebulizer had a more child-friendly design, then children would be more likely to ... NEBY to avoid the need to deliver medication via a nebulizer mask. The design ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to ... Medical Informatics . , Results of the comparative usability study demonstrate that a ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies ... Canada , Japan , Europe ... Rest of World. Annual estimates and forecasts are provided for the ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
(Date:12/8/2016)... 8, 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... today announced positive results from a Phase 3, ... the safety and efficacy of IDP-118 (halobetasol propionate ... psoriasis. Within the Phase 3 ... severe psoriasis, IDP-118 showed statistical significance to vehicle ...
Breaking Medicine Technology: